Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.63
-0.1100-2.32%
Post-market: 4.630.00000.00%19:30 EDT
Volume:2.99M
Turnover:14.05M
Market Cap:1.51B
PE:-11.22
High:4.86
Open:4.80
Low:4.63
Close:4.74
52wk High:7.30
52wk Low:3.69
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.59
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:3.90
PE(LYR):-13.58

Loading ...

Taysha Completes REVEAL Dosing, Advances Rett Gene Therapy

TIPRANKS
·
Jun 22

Taysha completes dosing in REVEAL pivotal trial of TSHA-102 for Rett syndrome

Reuters
·
Jun 22

Taysha Gene Therapies - Topline Data and FDA Feedback Expected in First Half of 2027

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - Tsha-102 Shows No Treatment-Related Saes or Dlts as of June 2026

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - Bla-Enabling Ppq Campaign for Tsha-102 Expected to Complete in Q4 2026

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies Announces Completion of Dosing in Reveal Pivotal Trial and Reports Longer-Term Clinical Data From Part a of Reveal Phase 1/2 Trials Evaluating Tsha-102 for Rett Syndrome

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - 100% of Reveal Part a Patients Gained or Regained Developmental Milestone by 12 Months

THOMSON REUTERS
·
Jun 22

Why Taysha Gene Therapies (TSHA) Is Up 12.4% After Institutions Tighten Their Grip On Shares

Simply Wall St.
·
Jun 20

Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue

Simply Wall St.
·
Jun 13

Taysha Gene Therapies grants new hires 714,700 RSUs, 468,600 options at $5.97 under inducement plan

Reuters
·
Jun 05

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Taysha Gene Therapies Shareholders Back Governance and Leadership

TIPRANKS
·
Jun 03

Taysha Gene Therapies shareholders elected two directors at annual meeting

Reuters
·
Jun 03

ASPIRE Rett Syndrome Trial Puts Taysha’s TSHA-102 Gene Therapy in Focus for Investors

TIPRANKS
·
May 23

A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway

Simply Wall St.
·
May 11

Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA

TIPRANKS
·
May 11

Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway

TIPRANKS
·
May 07

Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)

TIPRANKS
·
May 07

Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)

TIPRANKS
·
May 07

Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 06